Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults - PubMed (original) (raw)
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults
Anne M Fagan et al. Arch Neurol. 2007 Mar.
Abstract
Objectives: To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to discriminate early-stage Alzheimer disease (AD) (defined by clinical criteria and presence/absence of brain amyloid) from nondemented aging and to assess whether these biomarkers can predict future dementia in cognitively normal individuals.
Design: Evaluation of CSF beta-amyloid(40) (Abeta(40)), Abeta(42), tau, phosphorylated tau(181), and plasma Abeta(40) and Abeta(42) and longitudinal clinical follow-up (from 1 to 8 years).
Setting: Longitudinal studies of healthy aging and dementia through an AD research center.
Participants: Community-dwelling volunteers (n = 139) aged 60 to 91 years and clinically judged as cognitively normal (Clinical Dementia Rating [CDR], 0) or having very mild (CDR, 0.5) or mild (CDR, 1) AD dementia.
Results: Individuals with very mild or mild AD have reduced mean levels of CSF Abeta(42) and increased levels of CSF tau and phosphorylated tau(181). Cerebrospinal fluid Abeta(42) level completely corresponds with the presence or absence of brain amyloid (imaged with Pittsburgh Compound B) in demented and nondemented individuals. The CSF tau/Abeta(42) ratio (adjusted hazard ratio, 5.21; 95% confidence interval, 1.58-17.22) and phosphorylated tau(181)/Abeta(42) ratio (adjusted hazard ratio, 4.39; 95% confidence interval, 1.62-11.86) predict conversion from a CDR of 0 to a CDR greater than 0.
Conclusions: The very mildest symptomatic stage of AD exhibits the same CSF biomarker phenotype as more advanced AD. In addition, levels of CSF Abeta(42), when combined with amyloid imaging, augment clinical methods for identifying in individuals with brain amyloid deposits whether dementia is present or not. Importantly, CSF tau/Abeta(42) ratios show strong promise as antecedent (preclinical) biomarkers that predict future dementia in cognitively normal older adults.
Comment in
- Biomarkers in dementia.
Vanacore N, Galeotti F, Maggini M, Raschetti R. Vanacore N, et al. Arch Neurol. 2007 Sep;64(9):1356; author reply 1357-9. doi: 10.1001/archneur.64.9.1356. Arch Neurol. 2007. PMID: 17846281 No abstract available. - Medication use as a confounding factor in the use of the cerebrospinal fluid tau/beta-amyloid42 ratio.
Wong V. Wong V. Arch Neurol. 2007 Sep;64(9):1357; author reply 1357-9. doi: 10.1001/archneur.64.9.1357-a. Arch Neurol. 2007. PMID: 17846282 No abstract available.
Similar articles
- Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Stomrud E, et al. Arch Neurol. 2010 Feb;67(2):217-23. doi: 10.1001/archneurol.2009.316. Arch Neurol. 2010. PMID: 20142530 - Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T. Tapiola T, et al. Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596. Arch Neurol. 2009. PMID: 19273758 - CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ. Li G, et al. Neurology. 2007 Aug 14;69(7):631-9. doi: 10.1212/01.wnl.0000267428.62582.aa. Neurology. 2007. PMID: 17698783 - Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.
van Rossum IA, Vos S, Handels R, Visser PJ. van Rossum IA, et al. J Alzheimers Dis. 2010;20(3):881-91. doi: 10.3233/JAD-2010-091606. J Alzheimers Dis. 2010. PMID: 20413876 Review. - CSF biomarkers for mild cognitive impairment.
Blennow K. Blennow K. J Intern Med. 2004 Sep;256(3):224-34. doi: 10.1111/j.1365-2796.2004.01368.x. J Intern Med. 2004. PMID: 15324365 Review.
Cited by
- Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.
Barthélemy NR, Salvadó G, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL, Chen CD, Gordon BA, Li Y, La Joie R, Benzinger TLS, Morris JC, Mattsson-Carlgren N, Palmqvist S, Ossenkoppele R, Rabinovici GD, Stomrud E, Bateman RJ, Hansson O. Barthélemy NR, et al. Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21. Nat Med. 2024. PMID: 38382645 Free PMC article. - Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
Bellomo G, Cataldi S, Paciotti S, Paolini Paoletti F, Chiasserini D, Parnetti L. Bellomo G, et al. Alzheimers Res Ther. 2020 Sep 29;12(1):121. doi: 10.1186/s13195-020-00689-0. Alzheimers Res Ther. 2020. PMID: 32993776 Free PMC article. - Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment.
Ren P, Lo RY, Chapman BP, Mapstone M, Porsteinsson A, Lin F; Alzheimer’s Disease Neuroimaging Initiative. Ren P, et al. J Alzheimers Dis. 2016 Jul 25;54(1):69-78. doi: 10.3233/JAD-160368. J Alzheimers Dis. 2016. PMID: 27472880 Free PMC article. - Emerging roles of innate and adaptive immunity in Alzheimer's disease.
Chen X, Holtzman DM. Chen X, et al. Immunity. 2022 Dec 13;55(12):2236-2254. doi: 10.1016/j.immuni.2022.10.016. Epub 2022 Nov 8. Immunity. 2022. PMID: 36351425 Free PMC article. Review. - Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.
Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH. Handoko M, et al. JAMA Neurol. 2013 May;70(5):594-9. doi: 10.1001/jamaneurol.2013.48. JAMA Neurol. 2013. PMID: 23479202 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical